Joint Action1 Marras 2020

Disease Modifying Osteoarthritis Agents with Christoph Ladel

Current management approaches for osteoarthritis are usually targeted to symptoms. One way to mitigate the epidemic of osteoarthritis is to modify both its structural progression and symptomatic consequences in tandem a method known as disease modification, as distinct from symptom modification. These could potentially slow the speed of disease progression, completely halted or in an ideal world reverse the disease and regenerate the target tissue. At present, despite a number of positive trials there are no drugs that have garnered regulatory approval for this indication.

On this week's episode we discuss: what is disease modification, what have the clinical trials shown, what will the future of DMOADs look like and much more.

Christoph Ladel is working as Translational Medicine Expert. Most recent position was as team lead in the global clinical development department in Merck Healthcare KGaA (Darmstadt, Germany). In his role he was involved in design and execution of clinical studies from phase 1 to phase 3. Special responsibility was in the field of biomarker and imaging (MRI and x-ray) read-outs in clinical studies, mainly in osteoarthritis. He contributed to the respective teams to analyze data and to develop further stratification strategies based on biomarkers (incl. imaging) for studies in osteoarthritis.

Christoph trained as an immunologist with a PhD in immunopharmacology and immunotoxicology Dr Ladel has worked in different companies and different countries. Over the >15 years he was part of project teams or team leader in different projects for the discovery and development of therapies in osteoarthritis. Christoph is an internationally recognized scientist and has authored > 50 scientific peer reviewed publications and is co-inventor in more than 10 patents in the field of clinical strategies for osteoarthritis.

RESOURCES

Journal articles

CONNECT WITH US

Twitter: @ProfDavidHunter @jointactionorg
Email: hello@jointaction.info
Website: www.jointaction.info/podcast

If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

Hosted on Acast. See acast.com/privacy for more information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(175)

Your osteoarthritis listener questions with Vicky and David

Have you ever wondered whether your painful, stiff joints are just something you have to put up with, or whether there is actually something that can be done? On this week's episode of Joint Action, V...

19 Heinä 28min

Choosing shoes for osteoarthritis with A/Prof Kade Paterson

Could the shoes you wear every day be making your knee osteoarthritis better or worse? On this week's episode of Joint Action, Kade Paterson joins Professor David Hunter to explain why footwear matter...

5 Heinä 33min

Science without borders: a call to the osteoarthritis community

What happens to global science when funding is cut, borders close, and collaboration is threatened? In this special episode of Joint Action, Professor David Hunter reflects on the proposed changes to ...

21 Kesä 17min

When we say “the evidence shows this works,” who was actually included in that evidence? with Prof Christian Barton

When we say a treatment works for knee osteoarthritis, it is worth asking: works for whom? On this week's episode of Joint Action, Professor Christian Barton unpacks the blind spots in osteoarthritis ...

7 Kesä 30min

Your osteoarthritis listener questions with David and Vicky

This week on Joint Action, Vicky turns the tables and puts the questions to Professor David Hunter. Three listeners submitted questions spanning gut health, total knee replacement, and the frustrating...

24 Touko 22min

Do you really need surgery for your knee osteoarthritis? with Dr Howard Luks (2021)

The number of surgical procedures for musculoskeletal diseases such as osteoarthritis has increased exponentially over the past years, some of which are unnecessary and leave patients no better off th...

10 Touko 41min

Finding Responders: The Next Phase of OA Biomarkers with Dr Virginia Kraus, Dr Peter Mesenbrink, and Dr Jamie Collins

Can identifying the right patients and the right endpoints transform how we test new osteoarthritis treatments? On this week's episode of Joint Action, we unpack what the FNIH Biomarkers Consortium ha...

26 Huhti 29min

Defining the early-stage OA patient: the EsSKOA initiative with Dr Armaghan Mahmoudian

What does it actually mean to have 'early-stage' osteoarthritis, and does catching it sooner really make a difference? On this week's episode of Joint Action, learn more about early-stage knee osteoar...

12 Huhti 38min